Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Protein Biomarkers Identified for Dysglycemia Cardiovascular Risk

By LabMedica International staff writers
Posted on 01 Dec 2015
Impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes independently increase the risk of cardiovascular (CV) outcomes, and diabetes reduces life expectancy by up to 15 years. More...


Despite recent reductions in the incidence of CV outcomes in people with diabetes, both diabetes and lesser degrees of dysglycemia remain independent CV risk factor. The pathophysiologic reasons for this excess and for variations in incidence among people who already have established dysglycemia remain unclear.

A team of scientists working with a group at the Hamilton General Hospital (Hamilton, ON, Canada) recruited from a trial 12,537 people with either diabetes, impaired glucose tolerance or impaired fasting glucose and additional CV risk factors and followed for a median of 6.2 years. A subset of 8,494 (68%) also provided written consent for the collection and storage of a blood sample for future measurement of CV risk factors. Baseline fasting samples were collected, spun, separated ̧ and divided into 1.5-2.0 mL aliquots.

The team used a customized Human Discovery Multi-Analyte Profile 250+ panel on the LUMINEX 100/200platforms (Luminex; Austin, TX, USA). The DiscoveryMAP platform (Myriad RBM Inc.; Austin, TX, USA) measured a panel of 284 biomarkers in a serum sample from each participant. The panel included a combination of assays that had already been developed plus additional biomarker assays that were newly developed for the study.

The DiscoveryMAP platform successfully identified combinations of 15 protein biomarkers associated with cardiovascular (CV) events or death in people with pre-diabetes or early type 2 diabetes. After forcing in the clinical risk factors, 8 out of a possible 237 biomarkers each independently improved the ability to predict the CV composite outcome. Three of these eight biomarkers plus an additional four, a total of seven, were identified when the process was repeated for the expanded CV composite outcome. Three biomarkers, N-terminal of the prohormone brain natriuretic peptide (NT-proBNP), angiopoietin 2 and gluthathione S transferase alpha, were persistently identified in all models and for all outcomes.

Hertzel Gerstein, MD, the lead study investigator, said, “Our study is one of the largest scientific investigations in history to identify specific cardiovascular biomarkers associated with serious cardiovascular outcomes, including heart attacks, strokes and death. Our results highlight the potential value of cardiovascular biomarkers for identifying people with dysglycemia at the highest risk of future events.” The study was published on October 30, 2015, in the journal Circulation.

Related Links:

Hamilton General Hospital 
Luminex
Myriad RBM Inc. 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.